<DOC>
	<DOCNO>NCT00911157</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy ( measure rate recurrent symptomatic Venous Thromboembolism [ VTE ] ( i.e. , Pulmonary thromboembolism [ PE ] Deep Vein Thrombosis [ DVT ] ) ) safety GSK576428 initial treatment subject acute symptomatic DVT open-label design .</brief_summary>
	<brief_title>The Treatment Acute Deep Vein Thrombosis ( DVT ) GSK576428 ( Fondaparinux Sodium ) Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Confirmed diagnosis acute proximal DVT base contrastenhanced Multi detectorrow CT ( MDCT ) ( 10 day onset symptom DVT ) Age:20 year Gender : No restriction Hospitalization status : Subjects able stay hospital least initial treatment period Written inform consent subject him/herself his/her legally acceptable representative . Written inform consent subject 's legally acceptable representative must obtain subject incapable give consent Symptomatic PE Requirement surgical thrombectomy , catheter intervention thrombolytic therapy current DVT Subjects ( example , freefloating thrombus femoral vein ilium MDCT screening ) insertion inferior vena cava filter indicate subject inferior vena cava filter present Anticoagulant therapy least 24 hour treat current episode prior entry study Active , clinically significant bleed Thrombocytopenia ( platelet count &lt; 10×10⁴/µL screening ) Concurrent condition bleed risk ( e.g. , ulcer gastrointestinal tract , diverticulitis gastrointestinal tract , colitis , acute bacterial endocarditis , severe hypertension , severe diabetes ) bleed tendency Severe hepatic disorder Known hypersensitivity heparin , lowmolecularweight heparin ( LMWH ) warfarin Previous history cerebral hemorrhage Brain , spinal , ophthalmological surgery within 3 month prior entry study Previous history Heparininduced thrombocytopenia Patients anticoagulant therapy contraindicate take anticoagulant therapy due coexistent condition ( e.g . prosthetic heart valve implant ) Severe renal disorder ( serum creatinine &gt; 2.0 mg/dL [ 180 µmol/L ] screen ) well hydrate subject QT interval prolong ( QT interval correct Bazett 's formula [ QTcB ] ≥450 msec ; patient bundle branch block QTcB ≥480 msec ) screening Documented hypersensitivity contrast medium Use contraindicate drug combine injection contrast medium [ e.g. , antihyperglycemics , biguanides ( metformin hydrochloride , buformin hydrochloride ) ] Participation therapeutic drug study clinical study within 6 month prior entry study Previous participation study GSK576428 [ Fondaparinux Sodium ; include study Org31540/SR90107A ( exproject code ) ] previous exposure therapeutic dose GSK576428 Drug alcohol abuse Systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg Recent surgery within 3 day prior entry study Life expectancy &lt; 3 month Pregnant woman , nurse mother , woman may pregnant , woman contemplate pregnancy study period Others investigator subinvestigator considers eligible study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary thromboembolism</keyword>
	<keyword>contrast-enhanced MDCT</keyword>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>Fondaparinux sodium</keyword>
</DOC>